The estimated Net Worth of Alan L Crane is at least $11.1 Million dollars as of 12 August 2014. Alan Crane owns over 30,000 units of Pandion Therapeutics stock worth over $1,801,500 and over the last 20 years Alan sold PAND stock worth over $9,306,663.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Alan Crane PAND stock SEC Form 4 insiders trading
Alan has made over 15 trades of the Pandion Therapeutics stock since 2006, according to the Form 4 filled with the SEC. Most recently Alan bought 30,000 units of PAND stock worth $330,000 on 12 August 2014.
The largest trade Alan's ever made was selling 88,174 units of Pandion Therapeutics stock on 11 September 2006 worth over $1,323,492. On average, Alan trades about 24,833 units every 113 days since 2004. As of 12 August 2014 Alan still owns at least 30,000 units of Pandion Therapeutics stock.
You can see the complete history of Alan Crane stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Alan Crane's mailing address?
Alan's mailing address filed with the SEC is C/O PANDION THERAPEUTICS, INC., 134 COOLIDGE AVENUE, WATERTOWN, MA, 02472.
Insiders trading at Pandion Therapeutics
Over the last 4 years, insiders at Pandion Therapeutics have traded over $0 worth of Pandion Therapeutics stock and bought 1,743,632 units worth $30,815,954 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Kol..., and Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $9,518,646. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth $2,989,466.
What does Pandion Therapeutics's logo look like?
Complete history of Alan Crane stock trades at Momenta Pharmaceuticals, T2 Biosystems Inc, and Pandion Therapeutics
Pandion Therapeutics executives and stock owners
Pandion Therapeutics executives and other stock owners filed with the SEC include:
-
Capital Management, L.P.Kol...,
-
Nancy Stagliano,
Director -
Vikas Goyal,
See Remarks -
Joanne L. Viney,
See Remarks -
Partners Gp Viii, L.L.C.Pol...,
-
Rizzuto Carlo,
Director -
Jill Carroll,
Director -
Katina Dorton,
Director -
Donald Frail,
Director -
Christopher Fuglesang,
Director -
Gregg Beloff,
See Remarks -
Alan L Crane,
Director -
Mitchell Mutz,
Director -
Eric D Larson,
Vice President, Finance -
Daniel J. Becker,
Director -
Rahul Kakkar,
Chief Executive Officer -
Plc Gsk,
Director -
John Sundy,
Chief Medical Officer -
Edward D. Freedman,
Chief Operating Officer